In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk Sharing the Millennium Way

Executive Summary

Previous deals, such as those with Bayer and Monsanto, showcased Millennium Pharmaceuticals' technology integration capabilities and allowed it to leverage the value of its platform. It is now becoming more focused on using external relationships and acquisitions to forward integrate and build a product pipeline. Via a series of agreements with Aventis signed in June valued at $450 million, Millennium expects to build nothing less than the world's premier franchise in inflammation. And the agreements, including a tech transfer deal and a technology development deal along with the inflammation drug development collaboration and an equity investment by Aventis, appear to provide Millennium a way to fund drug development risk by leveraging its technology.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts